Mabwell (Shanghai) Bioscience Co., Ltd.: all 61 studies

Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior ChemoimmunotherapyNot yet recruitingNCT07831863Phase 3
• A Phase II Study of 9MW3811 in Patients With Pathological ScarRecruitingNCT07576608Phase 2
• A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07556848Phase 3
• A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsRecruitingNCT07466160Phase 1/2
• 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial CancerRecruitingNCT07314723Phase 2
• A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)RecruitingNCT07292714Phase 2
• First-in-human Study of 7MW4911 in Patients With Advanced Solid TumorsRecruitingNCT07265622Phase 1/2
• First-in-human Study of 7MW4911 in GI CancerRecruitingNCT07216560Phase 1/2
• A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsNot yet recruitingNCT06947226Phase 1/2
• 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological TumorsNot yet recruitingNCT06926998Phase 1/2
• A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCsRecruitingNCT06908928Phase 1
• 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06823427Phase 2
• A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingNCT06772766Phase 1
• A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingNCT06752746Phase 1
• A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerRecruitingNCT06692166Phase 3
• 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerRecruitingNCT06592326Phase 3
• A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerRecruitingNCT06492005Phase 2
• A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerRecruitingNCT06196736Phase 3
• 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerRecruitingNCT06079112Phase 1/2
• A Study of 7MW3711 in Subjects With Advanced Solid TumorsRecruitingNCT06008379Phase 1/2
• A Phase 1/2 Study of 7MW3711 in Advanced Solid TumorsRecruitingNCT06008366Phase 1/2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy SubjectsRecruitingNCT05912049Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid TumorsNot yet recruitingNCT05911984Phase 1
• A Clinical Study of 9MW2821 in Advanced Malignant Solid TumorsRecruitingNCT05773937Phase 1
• A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid TumorsRecruitingNCT05216965Phase 1/2
• A Phase I Study of 9MW4113 Injection Versus Dupixent®Active, not recruitingNCT07791342Phase 1
• A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisCompletedNCT06804590Phase 3
• Single Ascending Dose Study of 9MW3011 in Chinese Healthy SubjectCompletedNCT06389942Phase 1
• Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).Active, not recruitingNCT06175351Phase 1/2
• Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid TumorsActive, not recruitingNCT05990452Phase 1/2
• An Evaluation of 9MW1911 Injection in Healthy SubjectsCompletedNCT05803902Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy SubjectsCompletedNCT05740475Phase 1
• 6MW3511 in Patients With Advanced Solid TumorStatus unknownNCT05524194Phase 1/2
• A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
• A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory LymphomaStatus unknownNCT05446688Phase 2
• A Clinical Study of 6MW3211 in Patients With Renal CancerStatus unknownNCT05440045Phase 2
• A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung CancerStatus unknownNCT05431569Phase 2
• A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid TumorsSuspendedNCT05416749Phase 1/2
• A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure InfectionsStatus unknownNCT05339802Phase 2
• Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular EdemaStatus unknownNCT05324774Phase 3
• Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular EdemaCompletedNCT05324592Phase 1
• A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMDStatus unknownNCT05297292Phase 2/3
• Efficacy and Safety of MW031 in PMO SubjectsCompletedNCT05215977Phase 3
• A Clinical Study in Healthy Subjects to Evaluate 9MW1911 InjectionCompletedNCT05170243Phase 1
• A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant NeoplasmStatus unknownNCT05048160Phase 1/2
• Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid TumorsCompletedNCT04812509Phase 3
• Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy AdultsCompletedNCT04798326Phase 1
• Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy AdultsCompletedNCT04798313Phase 1
• A Clinical Study in Health Subjects to Evaluate 9MW1411 InjectionCompletedNCT04784312Phase 1
• A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19Status unknownNCT04627584Phase 2
• Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSFCompletedNCT04554056Phase 2/3
• A Clinical Study to Evaluate MW33 InjectionCompletedNCT04533048Phase 1
• Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid TumorsStatus unknownNCT04478461Phase 1
• Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03487055Phase 1
• Assessment of Anti-RANKL Antibody in Post-menopausal WomenStatus unknownNCT03242512Phase 1
• Assessment of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03239756Phase 1
• A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular DegenerationStatus unknownNCT03021785Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerStatus unknownNCT02725606Phase 1
• Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy SubjectsCompletedNCT02643901Phase 1
• Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular DegenerationStatus unknownNCT02613559Phase 1
• Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic TumorsCompletedNCT02156388Phase 1

← Mabwell (Shanghai) Bioscience Co., Ltd. overview and focus areas